Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

Inclusion Criteria: * 1\. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form. * 2\. Age ≥ 18 years. * 3\. Histopathology is confirmed non-small cell lung cancer . * 4.Patients with advanced non-small cell lung cancer (NSCLC) who experienced small cell transformation after EGFR-TKI resistance. * 5\. Predicted survival ≥ 12 weeks. . * 6\. ECOG 0-2. * 7\. Adequate bone marrow hematopoiesis and organ function. Exclusion Criteria: * 1\. History of other malignant tumors within 2 years. * 2\. Adverse events (except alopecia of any degree) of CTCAE \> grade 1 due to prior treatment (e.g., adjuvant chemotherapy, radiotherapy, etc.) prior to the first dose. * 3\. History of stroke or intracranial hemorrhage within 6 months prior to the first dose. * 4\. The presence of any severe or poorly controlled systemic disease, including poorly controlled hypertension and active bleeding in the judgment of the investigator. * 5\. Subjects with persistent or active infection, including but not limited to hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV) and COVID-19 infection. * 6\. Heart-related diseases or abnormalities * 7\. Past history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy or interstitial lung disease with active clinical symptoms, immune pneumonia caused by immunotherapy. * 8\. Refractory nausea and vomiting, chronic gastrointestinal disease, difficulty swallowing drugs, or inability to adequately absorb sunvozertinib or anlotinib due to previous bowel resection. * 9\. Live vaccine was given 2 weeks before the first medication. * 10\. Women who are breastfeeding or pregnant. * 11\. Hypersensitivity to the test drug and the ingredients. * 12\. Other conditions assessed by the investigator to be unsuitable for participation in the study.